Information Provided By: 
Fly News Breaks for July 22, 2019
ADPT
Jul 22, 2019 | 06:42 EDT
JPMorgan analyst Tycho Peterson started Adaptive Biotechnologies with an Overweight rating and $45 price target. As a leader in the "rapidly emerging," immune-driven medicine market, Adaptive has a "significantly" more attractive sales growth profile relative to peers, Peterson tells investors in a research note. He believes a valuation premium is justified and continues to see room for share upside.
News For ADPT From the Last 2 Days
There are no results for your query ADPT
